NITRO clinical trial information
Dataset Name: A Phase III, randomised trial of adding nitroglycerin to first line chemotherapy for advanced non-small cell lung cancer
Author: Prof Andrew Davidson, Royal Perth Hospital
Publisher: Thoracic Oncology Group Australasia
Funding: Cancer Council WA, Cancer Council QLD, Cancer Council NSW, National Health and Medical Research Council.
DOI: 10.58106/914n-jz74
Date made available: 2023
Subject: Chemotherapy
Dataset: Individual participant data
Patient sample size: 372
Dataset description: Patients starting one of five, prespecified, platinum-based doublets as first-line chemotherapy for advanced NSCLC were randomly allocated treatment with or without nitroglycerin 25 mg patches for 2 days before, the day of, and 2 days after, each chemotherapy infusion. Progression-free survival (PFS) was the primary end point. Accrual was stopped after the first interim analysis of 270 events. Chemotherapy was predominantly with carboplatin and gemcitabine (79%) or carboplatin and paclitaxel (18%). The final analysis included 345 events in 372 participants with a median follow-up of 33 months.
Requests for Data: Access can be requested via the Health Data Australia catalogue. Search for the ACTRN number in the catalogue to find datasets associated with this trial or email enquiries to info@thoraciconcology.org.au
